Aker BioMarine Yönetim

Yönetim kriter kontrolleri 3/4

Aker BioMarine CEO'su Matts Johansen, Jul2015 tarihinde atandı, in görev süresi 9.33 yıldır. in toplam yıllık tazminatı $ 688.81K olup, şirket hissesi ve opsiyonları dahil olmak üzere 61% maaş ve 39% ikramiyelerden oluşmaktadır. şirketin hisselerinin 1.25% ine doğrudan sahiptir ve bu hisseler NOK 65.04M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 3.2 yıl ve 3.7 yıldır.

Anahtar bilgiler

Matts Johansen

İcra Kurulu Başkanı

US$688.8k

Toplam tazminat

CEO maaş yüzdesi	61.0%
CEO görev süresi	9.3yrs
CEO sahipliği	1.2%
Yönetim ortalama görev süresi	3.2yrs
Yönetim Kurulu ortalama görev süresi	3.7yrs

Son yönetim güncellemeleri

Recent updates

Aker BioMarine (OB:AKBM) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of

Nov 08

Aker BioMarine AS' (OB:AKBM) Revenues Are Not Doing Enough For Some Investors

Nov 05

At kr102, Is It Time To Put Aker BioMarine AS (OB:AKBM) On Your Watch List?

Aug 20

Optimistic Investors Push Aker BioMarine AS (OB:AKBM) Shares Up 25% But Growth Is Lacking

Jul 19

What Does The Future Hold For Aker BioMarine AS (OB:AKBM)? These Analysts Have Been Cutting Their Estimates

Jul 16

There Are Reasons To Feel Uneasy About Aker BioMarine's (OB:AKBM) Returns On Capital

Jul 11

These 4 Measures Indicate That Aker BioMarine (OB:AKBM) Is Using Debt In A Risky Way

Jun 03

There's No Escaping Aker BioMarine AS' (OB:AKBM) Muted Revenues

Feb 15

There Are Reasons To Feel Uneasy About Aker BioMarine's (OB:AKBM) Returns On Capital

Nov 06

Estimating The Fair Value Of Aker BioMarine AS (OB:AKBM)

Sep 06

We Think You Should Be Aware Of Some Concerning Factors In Aker BioMarine's (OB:AKBM) Earnings

Nov 04

Aker BioMarine AS' (OB:AKBM) Has Found A Path To Profitability

Apr 13

Aker BioMarine AS (OB:AKBM) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Feb 18

Loss-Making Aker BioMarine AS (OB:AKBM) Set To Breakeven

Jan 07

CEO Tazminat Analizi

Matts Johansen'un ücretlendirmesi Aker BioMarine'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Sep 30 2024	n/a	n/a	US$3m
Jun 30 2024	n/a	n/a	-US$11m
Mar 31 2024	n/a	n/a	-US$8m
Dec 31 2023	US$689k	US$420k	-US$9m
Sep 30 2023	n/a	n/a	-US$15m
Jun 30 2023	n/a	n/a	-US$300k
Mar 31 2023	n/a	n/a	US$14m
Dec 31 2022	US$410k	US$401k	US$10m
Sep 30 2022	n/a	n/a	US$1m
Jun 30 2022	n/a	n/a	US$10m
Mar 31 2022	n/a	n/a	-US$8m
Dec 31 2021	US$467k	US$459k	-US$8m
Sep 30 2021	n/a	n/a	US$3m
Jun 30 2021	n/a	n/a	-US$8m
Mar 31 2021	n/a	n/a	-US$14m
Dec 31 2020	US$630k	US$420k	-US$5m
Sep 30 2020	n/a	n/a	-US$26m
Jun 30 2020	n/a	n/a	-US$28m
Mar 31 2020	n/a	n/a	-US$18m
Dec 31 2019	US$660k	US$450k	-US$24m

Tazminat ve Piyasa: Matts 'nin toplam tazminatı ($USD 688.81K ), Norwegian pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 467.38K ).

Tazminat ve Kazançlar: Matts 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.

CEO

Matts Johansen (48 yo)

9.3yrs

Görev süresi

US$688,813

Tazminat

Mr. Matts Johansen has been Chief Executive Officer at Aker BioMarine ASA since July 1, 2015. Mr. Johansen has been Chief Operating Officer of Aker Biomarine Antarctic AS since June 1, 2012. He serves as P...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Matts Johansen	Chief Executive Officer	9.3yrs	US$688.81k	1.25% NOK 65.0m
Katrine Klaveness	Chief Financial Officer	6.8yrs	US$378.29k	Veri yok
Hege Spaun	Chief Officer People & Communication	less than a year	US$221.24k	Veri yok
Trond Smedsrud	Chief Executive Officer of Emerging Business	no data	US$284.93k	Veri yok
Tone Lorentzen	Chief Operating Officer of Human Health Ingredients	no data	US$339.88k	Veri yok
Simon Seward	Chief Executive Officer of Human Health Ingredients	2.8yrs	US$306.31k	Veri yok
Seth French	Chief Executive Officer of Lang Pharma Nutrition Inc	3.2yrs	US$834.94k	Veri yok
Christopher Robin Vinter	Vice President of IR & Corporate Finance	no data	Veri yok	Veri yok
Lise Wiger	Financial Controller	no data	Veri yok	Veri yok

3.2yrs

Ortalama Görev Süresi

Deneyimli Yönetim: AKBM 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 3.2 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Kjell Røkke	Deputy Director	no data	Veri yok	Veri yok
Frank Reite	Director	no data	US$30.76k	Veri yok
Anne Harris	Independent Director	3.7yrs	US$48.75k	Veri yok
Ola Snøve	Chairman	10.8yrs	US$70.05k	0.98% NOK 51.0m
Cilia Indahl	Director	3.7yrs	US$30.76k	Veri yok
Sindre Skjong	Employee Representative Director	5.3yrs	Veri yok	Veri yok
Kimberly Mathisen	Director	2.6yrs	US$30.76k	Veri yok
Kristin Holmgren	Employee Representative Director	1.4yrs	Veri yok	0.0040% NOK 205.7k
Thomas Rokke	Employee Representative Director	1.4yrs	Veri yok	Veri yok

3.7yrs

Ortalama Görev Süresi

53yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: AKBM 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 3.7 yıldır).

Aker BioMarine Yönetim

Yönetim kriter kontrolleri 3/4

Anahtar bilgiler

Son yönetim güncellemeleri

No independent directors

Chairman recently bought kr5.4m worth of stock

Chief Executive Officer recently bought kr305k worth of stock

No independent directors

Aker BioMarine AS Appoints Mr. Øyvind Eriksen as an Observer to the Board on June 8, 2022

No independent directors

Recent updates

Consensus EPS estimates increase by 135%

Consensus EPS estimates fall by 17%

Aker BioMarine (OB:AKBM) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of

Aker BioMarine AS' (OB:AKBM) Revenues Are Not Doing Enough For Some Investors

New major risk - Financial position

Third quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

New major risk - Share price stability

Aker BioMarine AS Announces Extraordinary Dividend, Payable on 30 September 2024

At kr102, Is It Time To Put Aker BioMarine AS (OB:AKBM) On Your Watch List?

Optimistic Investors Push Aker BioMarine AS (OB:AKBM) Shares Up 25% But Growth Is Lacking

What Does The Future Hold For Aker BioMarine AS (OB:AKBM)? These Analysts Have Been Cutting Their Estimates

Second quarter 2024 earnings released: US$0.03 loss per share (vs US$0.005 profit in 2Q 2023)

Aker BioMarine AS Expects to Pay Extraordinary Dividend

Aker BioMarine AS Expects to Pay Extraordinary Dividend

There Are Reasons To Feel Uneasy About Aker BioMarine's (OB:AKBM) Returns On Capital

Aker BioMarine Antarctic Holding II AS completed the acquisition of Feed Ingredients business of Aker BioMarine AS (OB:AKBM).

AIP, LLC and Aker Capital ASA agreed to acquire Feed Ingredients business from Aker BioMarine AS (OB:AKBM).

AIP, LLC and Aker Capital ASA agreed to acquire Feed Ingredients business from Aker BioMarine AS (OB:AKBM).

These 4 Measures Indicate That Aker BioMarine (OB:AKBM) Is Using Debt In A Risky Way

First quarter 2024 earnings released: US$0.07 loss per share (vs US$0.20 loss in 1Q 2023)

Consensus EPS estimates fall by 69%

Full year 2023 earnings: EPS exceeds analyst expectations

Full year 2023 earnings released: US$0.10 loss per share (vs US$0.11 profit in FY 2022)

There's No Escaping Aker BioMarine AS' (OB:AKBM) Muted Revenues

There Are Reasons To Feel Uneasy About Aker BioMarine's (OB:AKBM) Returns On Capital

Third quarter 2023 earnings released: US$0.01 loss per share (vs US$0.05 profit in 3Q 2022)

Aker BioMarine AS to Report Q1, 2024 Results on Apr 25, 2024

No independent directors

Aker BioMarine ASA Receives Approval for LYSOVETA as New Dietary Suppient in the US

Aker BioMarine AS Provides Revenue Guidance for the Full Year of 2023

Aker BioMarine AS Provides Revenue Guidance for the Full Year of 2023

Consensus EPS estimates fall from profit to US$0.086 loss, revenue upgraded

Full year 2022 earnings: EPS misses analyst expectations

Consensus EPS estimates increase by 308%

Consensus EPS estimates fall by 65%

Chairman recently bought kr5.4m worth of stock

Full year 2022 earnings: EPS misses analyst expectations

Aker BioMarine ASA Announces Ministry of Food and Drug Safety in South Korea Approves Superba Krill Oil

Chief Executive Officer recently bought kr305k worth of stock

No independent directors

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Consensus forecasts updated

Consensus EPS estimates increase by 57%

Now 20% undervalued

Estimating The Fair Value Of Aker BioMarine AS (OB:AKBM)

Consensus EPS estimates increase by 136%

Consensus forecasts updated

Aker Biomarine as Reiterates Earnings Guidance for the Full Year of 2022

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Aker BioMarine AS Appoints Mr. Øyvind Eriksen as an Observer to the Board on June 8, 2022

Now 20% undervalued

Forecast breakeven date moved forward to 2022

Now 22% undervalued

First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

No independent directors

Aker Biomarine AS Announces Board Changes

Full year 2021 earnings: EPS and revenues miss analyst expectations

Aker BioMarine AS, Annual General Meeting, Apr 20, 2022

Aker BioMarine AS, Annual General Meeting, Apr 20, 2022

Consensus forecasts updated

Forecast breakeven date moved forward to 2022

Forecast breakeven date moved forward to 2022

Full year 2021 earnings: EPS and revenues miss analyst expectations

Chairman recently bought kr9.4m worth of stock

We Think You Should Be Aware Of Some Concerning Factors In Aker BioMarine's (OB:AKBM) Earnings

Chief Executive Officer recently bought kr3.3m worth of stock

Forecast breakeven pushed back to 2022

Forecast breakeven moved forward to 2021

First quarter 2021 earnings released: US$0.11 loss per share (vs US$0.08 loss in 1Q 2020)